Lactobacillus / TumCCA Cancer Research Results

LA, Lactobacillus: Click to Expand ⟱

Features: Bacteria

Lactobacillus acidophilus: Gram-positive, homofermentative, anaerobic microbe
Lactobacillus johnsonii: probiotic bacteria found in the human body and fermented foods.
Lactobacillus Plantarum: probiotic bacterium that may help with inflammation, blood sugar

Lactobacillus crispatus
Lactobacillus rhamnosus

Lactobacillus — A group of Gram-positive, non-spore-forming, lactic-acid-producing bacteria widely present in fermented foods and in the human gastrointestinal and female reproductive microbiota. Many strains are used as probiotics, but biological and anticancer effects are highly species- and strain-specific rather than properties of the genus as a whole. Formal classification is a live microbial/probiotic modality rather than a conventional small-molecule drug. Common shorthand is Lactobacillus spp. or lactobacilli. Following the 2020 taxonomic revision, several historically named Lactobacillus species were reassigned; for example, Lactobacillus plantarum is now Lactiplantibacillus plantarum and Lactobacillus rhamnosus is now Lacticaseibacillus rhamnosus, whereas L. acidophilus, L. johnsonii, and L. crispatus remain within Lactobacillus. Anticancer evidence is strongest for modulation of the intestinal or cervicovaginal microenvironment and host immunity, with direct tumor-cell effects largely preclinical.

Primary mechanisms (ranked):

Microbiome remodeling and epithelial-barrier support, including competitive exclusion of potentially pathogenic or pro-inflammatory organisms, production of lactic acid and antimicrobial metabolites, and improved tight-junction integrity.
Antitumor immune modulation (strain-dependent), including dendritic-cell regulation, IL-12 signaling, CD8+ T-cell priming and tumor-infiltrating cytotoxic T-cell activity; Lactiplantibacillus plantarum L168-derived indole-3-lactic acid is a well-characterized experimental example.
Suppression of chronic inflammatory signaling, including reduced pro-inflammatory cytokine and NF-κB-associated signaling in selected strains and models.
Direct induction of cancer-cell apoptosis and growth arrest by strain-derived metabolites, cell-free supernatants or bacterial components, with ↑ BAX/caspases and ↓ BCL-2 reported in several colorectal and other cancer models.
Modulation of tumor metabolism and hypoxic signaling, including HIF-1α, GLUT1 and glycolysis-related pathways in selected experimental systems; this is not established as a general Lactobacillus effect.
Cervicovaginal ecological protection, particularly with L. crispatus, where Lactobacillus-dominant microbiota are associated with lower high-risk HPV persistence and cervical dysplasia risk; direct inhibition of HPV E6/E7 and cancer-cell proliferation has also been demonstrated in vitro.

Bioavailability / PK relevance: Classical plasma pharmacokinetics are not applicable to live Lactobacillus probiotics. Relevant exposure depends on viable CFU delivered, strain survival through storage and gastric/bile conditions, delivery site, mucosal adherence, transient colonization, baseline microbiota and production of local metabolites. Systemic bacterial exposure is neither required nor desirable. Some microbial metabolites can enter host circulation, but their exposure differs substantially among strains and individuals.

In-vitro vs systemic exposure relevance: Many anticancer experiments expose cultured tumor cells directly to concentrated bacterial supernatants, extracts, purified metabolites or live organisms. These conditions cannot be equated with plasma concentrations after oral probiotic administration. Effects should therefore be interpreted primarily as local gastrointestinal, mucosal or mechanistic evidence unless corresponding metabolite exposure has been demonstrated in vivo.

Clinical evidence status: Preclinical + small human/RCT adjunct evidence. Multiple randomized studies in colorectal-cancer surgery have reported improvements in intestinal barrier function, microbiota composition, bowel recovery or postoperative infectious complications from probiotic or synbiotic mixtures containing Lactobacillus strains. Human evidence does not establish Lactobacillus as a tumor-eradicating therapy or demonstrate improved cancer-specific survival. It should be considered a strain-specific supportive or investigational adjunct rather than an anticancer treatment. Use of live probiotics warrants caution in severely immunocompromised patients, critically ill patients and patients with central venous catheters because rare Lactobacillus bacteremia or sepsis has been documented.

Lactobacillus Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	Primary Effect	Notes / Interpretation
1	Microbiome and epithelial barrier	↓ tumor-supportive dysbiosis indirectly	↑ barrier integrity ↑ microbial homeostasis	Reduces intestinal inflammation, pathogen translocation and disruption of epithelial tight junctions	Strongest clinically relevant mechanism; highly strain- and site-dependent
2	CD8 T-cell antitumor immunity	↓ tumor growth indirectly	↑ dendritic-cell IL-12 ↑ CD8+ T-cell activation	Enhances antitumor immune surveillance	Lactiplantibacillus plantarum L168-derived indole-3-lactic acid promotes IL12a expression and CD8+ T-cell function in colorectal-cancer models
3	Inflammatory signaling	↓ NF-κB-associated survival signaling (strain-dependent)	↓ excessive inflammatory signaling	Reduces tumor-promoting chronic inflammation	Direction varies substantially by species, strain, host tissue and immune context
4	Mitochondrial apoptosis	↑ BAX ↑ CASP3 ↑ CASP9 ↓ BCL-2	↔ or substantially less cytotoxicity in selected models	Promotes intrinsic apoptotic cell death	Mostly demonstrated using bacterial extracts or conditioned media at experimental concentrations
5	Cell cycle and proliferation	↓ proliferation ↑ cell-cycle arrest	↔ (model-dependent)	Limits cancer-cell expansion	Specific molecular targets differ markedly among strains and cancer types
6	HPV oncogenic signaling	↓ HPV E6/E7 ↓ CDK2 ↓ cyclin A ↑ p21	↔ protective cervicovaginal environment	Suppresses HPV-associated cervical cancer-cell proliferation	Reported particularly for supernatants from L. crispatus, L. jensenii and L. gasseri; largely preclinical
7	Cervicovaginal microbial ecology	↓ HPV persistence and carcinogenic environment indirectly	↑ Lactobacillus-dominant low-diversity microbiota	Supports epithelial and microbial homeostasis	L. crispatus is consistently more strongly associated with a favorable cervical environment than L. iners
8	HIF-1α and glucose metabolism	↓ HIF-1α ↓ GLUT1 ↓ glycolytic adaptation (model-dependent)	Not established	May impair hypoxia-associated metabolic adaptation	Reported in limited experimental models and should not be generalized across Lactobacillus strains
9	ROS and redox signaling	↑ or ↓ ROS (context-dependent)	↓ excessive oxidative stress in some inflammatory models	Can participate in apoptosis or tissue protection depending on strain and model	Not a uniform primary Lactobacillus mechanism; avoid assigning a single directional genus-level effect
10	Clinical Translation Constraint	Strain effects cannot be extrapolated to the genus	Rare bacteremia possible in high-risk hosts	Limits translation of experimental anticancer findings	Major constraints include strain identity, CFU viability, transient colonization, baseline microbiome heterogeneity, formulation differences, combined-species clinical trials and rare invasive infection in severely immunocompromised or critically ill patients

TumCCA, Tumor cell cycle arrest: Click to Expand ⟱

Source:

Type:

Tumor cell cycle arrest refers to the process by which cancer cells stop progressing through the cell cycle, which is the series of phases that a cell goes through to divide and replicate. This arrest can occur at various checkpoints in the cell cycle, including the G1, S, G2, and M phases. S, G1, G2, and M are the four phases of mitosis.

Scientific Papers found: Click to Expand⟱

8115-

LA,

Inhibitory Effect of Vaginal Lactobacillus Supernatants on Cervical Cancer Cells

in-vitro,

Cerv,

CaSki

TumCP↓, TumCCA↑, E6↓, E7↓, CDK2↓, cycA1/CCNA1↓, P21↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1, cycA1/CCNA1↓, 1, P21↑, 1, TumCCA↑, 1,

Migration(tgid=13) ⓘ

TumCP↓, 1,

Clinical Biomarkers(tgid=22) ⓘ

E6↓, 1, E7↓, 1,
Total Targets: 7

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: TumCCA, Tumor cell cycle arrest

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:108  Target#:322  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid